
NVST Stock Forecast & Price Target
NVST Analyst Ratings
Bulls say
Envista Holdings is supported by improving execution and innovation after recent investments, prompting management to raise medium-term targets for core revenue growth to 2-5%, adjusted EBITDA growth to 5-8%, and adjusted EPS growth to 7-11%, while reaffirming 100% free cash flow conversion. Growth is being driven by a healthier Specialty Products & Technologies portfolio, where implants are back to growth, the S-Series implant reached 18% of Nobel implant sales in 2Q across North America and Europe, and Spark remains a powerful margin lever with cost per aligner down 40% over the past three years. The thesis is further strengthened by high-margin consumables, a ~$450K global installed base supporting software and services adoption, and meaningful runway as roughly two-thirds of revenue comes from North America while about two-thirds of the global market is outside North America.
Bears say
Envista Holdings is viewed negatively because China orthodontic channel de-stocking tied to VBP is already pressuring 3Q sales by $10M, with only uncertain restocking in 4Q and potentially 1Q-27 and no clear evidence of a meaningful post-VBP volume lift. The concern is that if procedure pricing does not change, the company could face $30M-$45M of 2027 revenue risk, a similar hit to profitability, and $0.10-$0.20 of EPS risk, while pricing power across dental markets remains doubtful. On top of that, management’s likely refinancing of the $1.4B debt stack at a 200bp higher rate in mid-27 and a lower 15.5x multiple versus 16.5x reflect pressure from VBP and rising interest expense.
This aggregate rating is based on analysts' research of Envista Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.
NVST Analyst Forecast & Price Prediction
Start investing in NVST
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Envista Holdings Corp (NVST) Forecast
NVST Analyst Forecast & Price Prediction
Start investing in NVST
Order type
Buy in
Order amount
Est. shares
0 shares